Skip to main content
. Author manuscript; available in PMC: 2024 May 23.
Published in final edited form as: Cancer Cell. 2023 Sep 7;41(10):1817–1828.e9. doi: 10.1016/j.ccell.2023.08.008

Figure 4. Correlation between CMTM6 and CD58 expression in tumor cells and their association with response to ICB therapies.

Figure 4.

(A–D) Tumor biopsies from 88 melanoma and 102 colon cancer patients were analyzed for CMTM6 and CD58 expression levels using immunohistochemistry.

(A, C) Spearman correlation analysis was performed to evaluate the correlation between CMTM6 and CD58 expression levels in tumor cells.

(B and D) The association between CMTM6 and CD58 expression levels in tumor cells was analyzed using chi-squared tests. The samples were divided into CMTM6-high, CMTM6-low, CD58-high, and CD58-low groups based on the median expression values, and the results were presented as contingency tables.

(E) The association between CMTM6 and CD58 expression in tumor cells and the response to ICB therapies in the melanoma cohort. The expression levels of CMTM6 and CD58 were individually plotted against the patient’s response to therapy, classified as clinical benefit (Yes) or no clinical benefit (No). Patients with complete response (CR), partial response (PR), and stable disease (SD) lasting for 6 months or more were classified as having clinical benefit (Yes, n = 49), while patients with progressive disease or with an SD for less than 6 months were categorized as having no clinical benefit (No, n = 39). Comparisons were made between patients that showed clinical benefit (Yes) and those that showed no clinical benefit (No) using the Wilcoxon rank-sum test. Statistical significance is indicated by *p < 0.05.